Kaneka Acquires EndoStream Medical

January 9, 2025—Kaneka Corporation announced that it acquired 96.8% of the shares of EndoStream Medical Ltd. (ESM) on December 23, 2024.

ESM, a manufacturer of technologies for cerebrovascular diseases, is headquartered in Or Akiva, Israel. The company is developing the Nautilus device for the treatment of wide neck cerebral aneurysms. The device is designed to be used in combination with an aneurysm embolization coil.

Kaneka, based in Tokyo, Japan, is a developer of devices for cardiac, peripheral vascular, and cerebrovascular diseases, as well as devices used in the treatment of gastrointestinal tract diseases.

According to Kaneka, ESM’s Nautilus device has received regulatory approval in Europe. In the United States, the approval and launch of Nautilus is planned for the spring of 2026. Approval in Japan is anticipated for 2027, advised the company.

The press release stated that by combining Kaneka’s manufacturing and ESM’s technology, the companies plan to jointly develop new medical devices, mainly for cerebrovascular treatment.

Kaneka noted that among other technologies, it has the i-ED coil, an embolization coil intended to prevent damage to cerebral aneurysms that cause subarachnoid hemorrhage.

In February 2023, ESM announced commencement of enrollment in the TORNADO-US clinical study of the Nautilus device in the United States. That announcement noted that the i-ED Coil was used with the Nautilus in the first patient treated in TORNADO-US.